Human embryonic stem cells (hESCs) and -derivatives are promising cell sources due to their unique ability of differentiation into specific lineage in regenerative medicine. Recently, many pharmaceutical companies focused their attention on the potent...
Human embryonic stem cells (hESCs) and -derivatives are promising cell sources due to their unique ability of differentiation into specific lineage in regenerative medicine. Recently, many pharmaceutical companies focused their attention on the potential of hESCs as screening models for development of new drugs. Pre-clinical model of drug screening is animal-based model, therefore, interpretation of responses to certain chemical is different from that of human. In this regards, human cell-based model is necessary and the hESCs and differentiated cells are valuable as screening platform. In this review, we highlighted the recent researches using hESC-derived cardiomyocytes (CMs) as drug screening model.